AMENDMENTS TO THE CLAIMS

This listing of the claims replaces all prior versions and listings of the claims for this application. Within this listing of the claims, claims 1, 20, and 43 are currently amended; claims 13-15 and 19 are withdrawn as drawn to a non-elected species; and claims 25, 29-42, 44-49, and 51-61 are canceled (claims 40-42 were canceled as a result of a restriction requirement).

1. **(Currently amended)** A method for enhancing sexual desire and responsiveness in a female individual, comprising: (a) orally administering a therapeutically effective amount of an orally active androgenic agent as a first active agent; and (b) administering to the individual a therapeutically effective amount of a second active agent selected from the group consisting of ~~rho kinase inhibitors~~ the rho kinase inhibitor Y-27632, melanocortin peptides having the sequence His-Phe-Arg-Try or His-D-Phe-Arg-Try, ~~endothelin antagonists~~ phenoxyphenylacetic acids and derivatives thereof, growth factors, cytokines, the selective androgen receptor modulators LGD2226 and LGD1331, ~~neuropeptides~~ bradykinin, kallidin, des-Arg^9-bradykinin, des-Arg^{10}-kallidin, des-Arg^9-[Leu^8]-bradykinin, [D-Phe^7]-bradykinin, HOE 140, neuropeptide Y, calcitonin gene-related peptide (cGRP), enkaphalins, Met^5-enkaphalin, Leu^5-enkephalin, α-endorphin, β-endorphin, γ-endorphin, α-neo-endorphin, β-endorphin, dynophin, γ-aminobutyric acid, acetylcholine, dopamine, epinephrine, 5-hydroxytryptamine, substance P, serotonin, catecholamines, glutamate, taurine, glycine, ~~amino acids~~ arginine, phenylalanine, leucine, isoleucine, methionine, valine, serine, proline, threonine, alanine, tyrosine, histidine, glutamine, asparagines, lysine, aspartic acid, glutamic acid, cysteine, tryptophan and derivatives thereof, serotonin antagonists, dopamine antagonists, potassium channel openers, potassium channel blockers, ~~non-androgenic steroids,~~ and combinations thereof, wherein administration is on an as-needed basis.

2. **(Original)** The method of claim 1, wherein the androgenic agent is contained within an oral dosage form.

3. **(Original)** The method of claim 2, wherein the pharmaceutical formulation is comprised of an immediate release dosage form, and the androgenic agent is administered about 0.25 to 72 hours prior to sexual activity.

4. **(Original)** The method of claim 3, wherein the androgenic agent is administered about 0.5 to 48 hours prior to anticipated sexual activity.

5. **(Original)** The method of claim 4, wherein the androgenic agent is administered about 1 to 24 hours prior to anticipated sexual activity.

6. **(Original)** The method of claim 5, wherein the androgenic agent is administered about 1 to 12 hours prior to anticipated sexual activity.

7. **(Original)** The method of claim 6, wherein the androgenic agent is administered about 1 to 4 hours prior to anticipated sexual activity.

8. **(Original)** The method of claim 2, wherein the pharmaceutical formulation is comprised of a sustained release dosage form.

9. **(Original)** The method of claim 8, wherein following administration, the sustained release dosage form provides release of the androgenic agent over a drug delivery period in the range of about 4 to 72 hours.

10. **(Original)** The method of claim 9, wherein the drug delivery period is in the range of about 4 to 48 hours.

11. **(Original)** The method of claim 10, wherein the drug delivery period is in the range of about 4 to 24 hours.

12. **(Original)** The method of claim 2 wherein the androgenic agent is selected from the group consisting of orally active testosterone esters, orally active dihydrotestosterone esters, methyl testosterone, dehydroepiandrosterone, and combinations thereof.

13. **(Withdrawn)** The method of claim 12, wherein the androgenic agent is an orally active testosterone ester.

14. **(Withdrawn)** The method of claim 13, wherein the orally active testosterone ester is selected from the group consisting of testosterone propionate, testosterone undecanoate, and testosterone C_4-C_6 alkyl-substituted cycloalkylcarboxylates.

15. **(Withdrawn)** The method of claim 14, wherein the orally active testosterone ester is testosterone propionate.

16. **(Original)** The method of claim 12, wherein the androgenic agent is an orally active dihydrotestosterone ester.

17. **(Original)** The method of claim 16, wherein the orally active dihydrotestosterone ester is selected from the group consisting of dihydrotestosterone propionate, dihydrotestosterone undecanoate, and dihydrotestosterone C_4-C_6 alkyl-substituted cycloalkylcarboxylates.

18. **(Original)** The method of claim 17, wherein the orally active dihydrotestosterone ester is dihydrotestosterone propionate.

19. **(Withdrawn)** The method of claim 12, wherein the androgenic agent is selected from the group consisting of testosterone decanoate, testosterone pentadecanoate, testosterone undecanoate, testosterone pelargonate, testosterone tridecanoate, testosterone palmitate, testosterone caprate, testosterone isocaprate, testosterone α-methylcaprate, testosterone β-methylcaprate, testosterone laurate, testosterone α-methylpelargonate, testosterone β-methylpelargonate, testosterone β,β-dimethylpelargonate, testosterone β-(p-methyl-cyclohexyl)propionate, testosterone β-(p-ethyl-cyclohexyl)-propionate, testosterone β-(cycloheptyl)-propionate, testosterone α-methyl-β-cyclohexyl propionate, testosterone β-methyl-β-cyclohexyl propionate, testosterone cyclododecylcarboxylate, testosterone adamantine-1'-carboxylate, testosterone adamant-1'-yl-acetate, testosterone methyl-β-cyclohexyl propionate, testosterone β-(bicyclo-[2,2,2-oct-1'-yl)-propionate, dihydrotestosterone decanoate, dihydrotestosterone pentadecanoate, dihydrotestosterone undecanoate, dihydrotestosterone pelargonate, dihydrotestosterone tridecanoate, dihydrotestosterone palmitate, dihydrotestosterone caprate, dihydrotestosterone isocaprate, dihydrotestosterone α-methylcaprate, dihydrotestosterone β-methylcaprate, dihydrotestosterone laurate, dihydrotestosterone α-methylpelargonate, dihydrotestosterone β-methylpelargonate, dihydrotestosterone β,β-dimethylpelargonate, dihydrotestosterone β-(p-methyl-cyclohexyl)propionate, dihydrotestosterone β-(β-ethyl-cyclohexyl)-propionate, dihydrotestosterone β-(cycloheptyl)-propionate, dihydrotestosterone α-methyl-β-cyclohexyl propionate, dihydrotestosterone β-methyl-β-cyclohexyl propionate, dihydrotestosterone cyclododecylcarboxylate, dihydrotestosterone adamantine-1'-carboxylate, dihydrotestosterone adamant-1'-yl-acetate, dihydrotestosterone methyl-β-

cyclohexyl propionate, dihydrotestosterone β-(bicyclo-[2,2,2-oct-1'-yl)-propionate, and combinations thereof.

20. **(Currently amended)** The method of claim [[19]] 1, wherein the dosage form further includes a lipoidal carrier effective to enhance the oral bioavailability of the androgenic agent.

21. **(Original)** The method of claim 1, wherein the therapeutically effective amount is in the range of about 1 μg to about 250 mg.

22. **(Original)** The method of claim 21, wherein the therapeutically effective amount is in the range of about 1 μg to about 150 mg.

23. **(Original)** The method of claim 22, wherein the therapeutically effective amount is in the range of about 10 μg to about 100 mg.

24. **(Original)** The method of claim 2, wherein the therapeutically effective amount of the androgenic agent in the dosage form is a unit dosage.

25. **(Canceled)**

26. **(Previously presented)** The method of claim 1, wherein the second active agent is administered with the androgenic agent.

27. **(Previously presented)** The method of claim 1, wherein the second active agent is administered prior to administration of the androgenic agent.

28. **(Previously presented)** The method of claim 1, wherein the second active agent is administered after administration of the androgenic agent.

29-42. **(Canceled)**

43. **(Currently amended)** The method of claim [[25]] 1, wherein administration of the second active agent is topical, transdermal, sublingual, intranasal, buccal, rectal, parenteral, or by inhalation.

44-49. **(Canceled)**

50. **(Previously presented)** A method for enhancing sexual desire and responsiveness in a female individual, comprising orally administering an orally active androgenic agent to the individual in an amount effective to provide a blood level of the agent or a metabolite thereof that approximates the blood level of the agent or a metabolite thereof during ovulation, wherein said administering is carried out on an as-needed basis.

51-61. **(Canceled)**